Liver Steatosis Predicts Poor Outcomes in Chronic HCV Liver Steatosis Predicts Poor Outcomes in Chronic HCV

A new study finds that the presence of liver steatosis may be a risk factor for all-cause mortality and hepatocellular carcinoma among chronic hepatitis C patients.Journal of Viral Hepatitis
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Related Links:

Liliana Chemello Direct antiviral agents (DAAs) have excellent efficacy against chronic hepatitis C virus (HCV) infection. Despite this strength, recent studies raised concerns about an unexpected hepatocellular carcinoma (HCC) occurrence rate after DAA therapy. In this exploratory case-control study, we evaluated the potential use of miRNAs as serum biomarkers for the detection of early HCC in DAA-treated patients. In the discovery phase, the circulating miRNome was assessed in 10 matched patients with (HCC+) or without HCC (HCC−) occurrence. Microarray analysis was performed before (T0) and after one month...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Authors: Stasi C, Sadalla S, Carradori E, Monti M, Petraccia L, Madia F, Gragnani L, Zignego AL Abstract BACKGROUND. New direct-acting antiviral drugs can eradicate hepatitis C virus (HCV) infection in over 90% of patients and can even reduce the risk of complications in advanced fibrosis/cirrhosis. The aims of this study were to evaluate 1) changes in fibrosis during and after antiviral treatment and 2) incidence of hepatocarcinoma and mortality in various fibrosis stages.METHODS. This is a longitudinal monocentric prospective study. Blood and instrumental examinations were evaluated at baseline, at the end of the...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
This study was done to elucidate the influence of direct-acting antiviral (DAA) agents on the recurrence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-related HCC (HCV-HCC) after curative therapies. HCV-HCC patients who received curative therapies and obtained a complete response were analyzed. From January 2017 to September 2017, 112 HCV-HCC patients received DAA and obtained a sustained virological response (SVR). From January 2006 to December 2014, another 345 HCV-HCC patients received peg-interferon-based treatment and 118 obtained SVR. From January 2012 to December 2016, 248 HCV-HCC patien...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
Authors: Raafat Rowida I, Eshra KA, El-Sharaby RM, Eissa R, Saied SM, Amer I, El Sharawy S Abstract BACKGROUND: As hepatocellular carcinoma (HCC) arising from chronic hepatitis C virus (HCV) infection in liver cirrhosis is a major problem in public health, early and rapid prediction of HCC is urgent. We hypothesised that a single nucleotide polymorphism in the Apa1 SNP in the vitamin D receptor may help diagnosis. METHODS: We recruited 3 groups: 80 HCC patients with HCV cirrhosis, 80 HCV cirrhotic patients free of HCC and 80 healthy controls. Apa1 rs7975232 SNP was detected by PCR- RFLP technique. Routine labor...
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research
Sorafenib is of proven efficacy in treating patients of hepatocellular carcinoma (HCC). Our study was aimed to determine the factors influence the sorafenib efficacy. We evaluated data of HCC patients receiving sorafenib from June 2012 to October 2016. All HCC cases were of the Barcelona Clinic Liver Cancer (BCLC) classification stage C. The exclusion criteria: those of BCLC classification stage A or B, with the absence or co-infection of hepatitis B (HBV) and hepatitis C (HCV). The presence of HBV, HCV, macoscopic vascular invasion (MVI) or extrahepatic spread (EHS) was recorded for each patient. Time-to-progression (TTP...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Chronic hepatitis C virus (HCV) infection is a major public health threat, with an estimated 71 million individuals affected worldwide.[1] In 2015, it is estimated that only 20% of these individuals were aware of their HCV infection.[1] In 2016, approximately 13% of those aware of having chronic HCV infection were being treated.[2] Approximately 15 –30% of patients with chronic HCV infection will develop cirrhosis within 20 years[3] and, if left untreated, these patients are at risk for developing hepatic decompensation and hepatocellular carcinoma, ultimately leading to increased liver-related mortality.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Background/Aims: The course of hepatitis C infection (HCV) in patients with thalassemia has not been adequately studied and management has not been optimized. The current prospective longitudinal study assessed the clinical course, outcome, progression and management of recently acquired HCV in patients with transfusion dependent thalassemia major versus acute HCV without thalassemia.Methods: A well-characterized cohort of patients with thalassemia and recent HCV infection or recent HCV without thalassemia were enrolled and prospectively followed. The blood transfusion needs and chelating agents were determined. Liver func...
Source: Mediterranean Journal of Hematology and Infectious Diseases - Category: Hematology Source Type: research
CONCLUSIONS: The six serum miRNAs can be utilized as a surrogate and non-invasive biomarker for HCV-related HCC diagnosis. PMID: 31658041 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
This study examined 196 patients for an estimation study (104 patients with HCC, 52 with liver cirrhosis and 40 with liver fibrosis) and 122 patients for the validation study (80 patients with HCC, 42 with liver cirrhosis). All patients were positive for hepatitis C virus. Four markers were measured: Midkine and thioredoxin using ELISA, 1-methyladenosine and 1-methylguanosine using a gas chromatography-mass spectrometry (GC-MS). The results were compared with alpha-fetoprotein (AFP). The performance of the model was estimated in BCLC, CLIP and Okuda staging systems of HCC. RESULTS: The model yielded high performance wi...
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Authors: El-Kady DS, Ali NA, Sayed AH, Abdelhaliem MM, Elmegeed GA, Ahmed HH Abstract Cancer is recognized as one of the most prevalent contributors to mortality in several nations and it remains one of the common health issues globally. In particular, hepatocellular carcinoma (HCC) has become a public health problem along with the increase of hepatitis B (HBV) and hepatitis C (HCV) virus infections. Based on this fact, our study goaled to synthesize newly hybrid drugs containing heterocyclic rings incorporated to steroid moiety and to examine the potential antitumor activity of the newly designed heterosteroid der...
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
More News: Cancer & Oncology | Carcinoma | Gastroenterology | Health | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | Liver | Liver Cancer | Study | Urology & Nephrology